Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk
New York, January 7, 2026, 09:54 EST — Regular session Pfizer shares rose about 0.9% to $25.67 in morning trade on Wednesday, even as investors weighed a new patent lawsuit tied to its COVID-19 vaccine and a cautious call from UBS. UBS began coverage of Pfizer with a Neutral rating and a $25 price target, pointing to what it described as revenue uncertainty as several big drugs face patent expirations in coming years. UBS estimated roughly $15 billion to $20 billion of annual revenue is exposed to loss of exclusivity — when patents expire and cheaper rivals move in —